CN101940620B - Medicinal composition for treating diabetes mellitus and application thereof - Google Patents
Medicinal composition for treating diabetes mellitus and application thereof Download PDFInfo
- Publication number
- CN101940620B CN101940620B CN2010102825443A CN201010282544A CN101940620B CN 101940620 B CN101940620 B CN 101940620B CN 2010102825443 A CN2010102825443 A CN 2010102825443A CN 201010282544 A CN201010282544 A CN 201010282544A CN 101940620 B CN101940620 B CN 101940620B
- Authority
- CN
- China
- Prior art keywords
- extract
- chromium
- radix
- pharmaceutical composition
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 61
- 241000508269 Psidium Species 0.000 claims abstract description 40
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000011651 chromium Substances 0.000 claims abstract description 27
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 229940046374 chromium picolinate Drugs 0.000 claims abstract description 18
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910001430 chromium ion Inorganic materials 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 119
- 210000004369 blood Anatomy 0.000 claims description 71
- 239000008280 blood Substances 0.000 claims description 71
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 238000001035 drying Methods 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 20
- 229940125396 insulin Drugs 0.000 claims description 20
- 239000009636 Huang Qi Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 18
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 12
- 150000004676 glycans Chemical class 0.000 claims description 11
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 11
- -1 alkaloid compounds Chemical class 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 8
- 241001061264 Astragalus Species 0.000 claims description 7
- 235000006533 astragalus Nutrition 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 210000004233 talus Anatomy 0.000 claims description 7
- XHFVDZNDZCNTLT-UHFFFAOYSA-H chromium(3+);tricarbonate Chemical compound [Cr+3].[Cr+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O XHFVDZNDZCNTLT-UHFFFAOYSA-H 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 229930013930 alkaloid Natural products 0.000 claims description 4
- 229930185803 charantin Natural products 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 4
- 150000002215 flavonoids Chemical class 0.000 claims description 4
- 235000017173 flavonoids Nutrition 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- LXMQZGGLHVSEBA-UHFFFAOYSA-N chromium;trihydrate Chemical compound O.O.O.[Cr] LXMQZGGLHVSEBA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002212 flavone derivatives Chemical class 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 40
- 229940079593 drug Drugs 0.000 abstract description 27
- 208000021959 Abnormal metabolism Diseases 0.000 abstract description 2
- 241000721047 Danaus plexippus Species 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000006371 metabolic abnormality Effects 0.000 abstract description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract 2
- 235000008524 evening primrose extract Nutrition 0.000 abstract 1
- 229940089020 evening primrose oil Drugs 0.000 abstract 1
- 239000010475 evening primrose oil Substances 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 description 39
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 30
- 239000008103 glucose Substances 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 235000019198 oils Nutrition 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000002156 mixing Methods 0.000 description 20
- 229920002472 Starch Polymers 0.000 description 18
- 239000008107 starch Substances 0.000 description 17
- 235000019698 starch Nutrition 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 16
- 108090001061 Insulin Proteins 0.000 description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 235000019197 fats Nutrition 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000007598 dipping method Methods 0.000 description 13
- 238000010298 pulverizing process Methods 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 206010013786 Dry skin Diseases 0.000 description 10
- 230000001476 alcoholic effect Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000001603 reducing effect Effects 0.000 description 10
- 239000007779 soft material Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 229960004756 ethanol Drugs 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical group C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 8
- 201000001421 hyperglycemia Diseases 0.000 description 8
- 230000002218 hypoglycaemic effect Effects 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 210000000496 pancreas Anatomy 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 235000015424 sodium Nutrition 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 229960003943 hypromellose Drugs 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 229960001381 glipizide Drugs 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000004153 islets of langerhan Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 3
- 229960002733 gamolenic acid Drugs 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 2
- 102100036721 Insulin receptor Human genes 0.000 description 2
- 244000302512 Momordica charantia Species 0.000 description 2
- 235000009811 Momordica charantia Nutrition 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940083580 glipizide 5 mg Drugs 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 150000001845 chromium compounds Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229960003271 rosiglitazone maleate Drugs 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicinal composition for treating diabetes mellitus and application thereof. The medicinal composition contains 20 to 200 parts of guava by weight, 0.01 to 0.2 part (converted to the weight of chromium) of medicinal compound containing chromium ions by weight, and 0.1 to 2 parts of evening primrose oil weight. The medicinal composition is a compound preparation combined by traditional Chinese herb and west medicine chromium picolinate to ensure that the two medicines can play the effect of synergy, so the medicinal composition not only has the advantages of accurate curative effect and quick response of the west medicine, but also can play the effects of harmonized medicines, compatibility between monarch and ministerial medicines, and abnormal metabolism balancing in human bodies in the traditional Chinese medicinal composition, and has the effect of treating both principal and secondary aspect of diabetes mellitus, hyperlipemia, in particular II-type diabetes mellitus with the hyperlipemia.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and application thereof of treating diabetes.
Background technology
Raising along with living standards of the people; Be accompanied by the variation of dietetic life; " affluenza " such as diabetes, hyperlipidemia, hypertension become serious in the world Chronic Non-Communicable Diseases after tumor, cardiovascular disease; And the increase year by year of its sickness rate, if can not be effectively controlled, its various secondary diseases, complication etc. are with the health of serious harm human body.For a long time; Though the traditional Chinese medical science, Chinese medicine are started with from effecting a permanent cure; Dialectical executing controlled, but from blood sugar lowering, blood fat fast and accurately gap arranged still, and the treatment of supplementation with insulin that doctor trained in Western medicine, Western medicine are taked or OHA, lipid lowerers; Though blood glucose, blood fat are controlled within the ideal scope, to diabetes, carrying out property blood vessel, nervous lesion, the blood vessel injury of hyperlipidemia etc. still do not have preventing and delay that it takes place, the effective measures of development.
Fructus psidii guajavae immaturus has the manual inseminating and loses to wild kind in areas such as China Fujian, Guangdong, Guangxi, Sichuan, Guizhou, Taiwan, be a kind of rich in natural resources.Existing research shows, is rich in flavone compound and polysaccharide compositions such as Quercetin in the Fructus psidii guajavae immaturus, compares with other Chinese medicine extract to have more excellent hypoglycemic effect.Also have and disclose the method that is used in combination with guava extract and some chemical classes medicines in some documents; But in order to play the effect identical with chemical medicine; Usually the large usage quantity of Chinese medicine extract, generally all more than 300g/kg, heavy dose of medication meeting increases production cost, the patient takes inconvenience; And large dose oral administration can bring a lot of side effect, brings great burden for intravital internal organs such as kidney, liver etc.Zoopery shows that the picked-up meeting of heavy dose of guava extract brings great side effect to gastrointestinal tract, and the symptom that occur feeling sick, vomiting, body weight significantly alleviates has increased patient's misery.And containing the Chinese medicine that several flavors to tens are distinguished the flavor of in traditional pure Chinese prescription, onset is slow, difficult quality control.
Summary of the invention
One of goal of the invention of the present invention is to provide a kind of pharmaceutical composition of treating diabetes, and this pharmaceutical composition is a kind of can starting with from effecting a permanent cure, again the compound pharmaceutical composition of the Chinese medicine preparation of blood sugar lowering, blood fat and Western medicine prepn fast and accurately.
Technical scheme of the present invention is following:
A kind of medical compounds; The component that contains following parts by weight: guava extract 20-200 part; Medicinal compound 0.01-0.2 part of containing chromium ion, Radix Oenotherae erythrosepalae oil 0.1-2 part, the wherein said content that contains the medicinal compound of chromium ion is the weight in chromium.
Preferably; The said medicinal compound that contains chromium ion is one or more in chromium picolinate, nicotinic acid chromium, chromic oxide gel, chromium carbonate, chromic oxide and the Chlorizate chromium; Preferably, the weight portion of Radix Puerariae extract is that the weight portion of 40-200, Radix Astragali extract is that the weight portion of 20-170, Fructus Momordicae charantiae extract is that the weight portion of 10-100, Radix Ophiopogonis is that the weight portion of 20-170, Folium Mori extract is 20-170.
Preferably, said pharmaceutical composition also comprises one or more in Radix Puerariae extract, Radix Astragali extract, Fructus Momordicae charantiae extract, Radix Ophiopogonis, the Folium Mori extract.
In the preferred embodiment of pharmaceutical composition of the present invention, said composition contains the component of following weight fraction:
Guava extract 50-100 part chromium picolinate 0.025-0.1 part
Radix Astragali extract 30-160 part Fructus Momordicae charantiae extract 10-100 part
Radix Ophiopogonis 30-160 part Radix Oenotherae erythrosepalae oil 0.15-1 part,
The parts by weight of wherein said chromium picolinate are with the cubage of chromium.
Preferably; Said guava extract, Radix Puerariae extract, Radix Astragali extract, Fructus Momordicae charantiae extract and Folium Mori extract are respectively by Fructus psidii guajavae immaturus, Radix Puerariae, the Radix Astragali, Fructus Momordicae charantiae and Folium Mori after through alcohol extraction or water extraction, drying and crushing, and the effective ingredient that above-mentioned each extract comprises is Fructus psidii guajavae immaturus total flavonoid, Fructus psidii guajavae immaturus polysaccharide and Fructus psidii guajavae immaturus polyphenol, puerarin and Radix Puerariae flavone, astragalus polysaccharides, Charantin, Fructus Momordicae charantiae para-insulin, Fructus Momordicae charantiae para-insulin peptide class, Folium Mori alkaloid compounds.
The guava extract of pharmaceutical composition of the present invention is Fructus psidii guajavae immaturus meat extract and/or Folium Psidii Guajavae extract.
Preferably, also comprise pharmaceutically acceptable carrier auxiliary material, be prepared into medical dosage form or functional health product.Said carrier auxiliary material such as dextrin; Lactose; Amylum pregelatinisatum; Excipient such as microcrystalline Cellulose; Dried starch; Carboxymethyl starch sodium; Low-substituted hydroxypropyl cellulose; Crosslinked polyethylene is than disintegrating agents such as lattice alkane ketone; Ethanol; Starch slurry; Sodium carboxymethyl cellulose; Methylcellulose; Binding agents such as ethyl cellulose; Lubricants such as magnesium stearate; Sodium stearate; Sodium lauryl sulphate; The phospholipid surfactant; Parabens; Antiseptic such as benzoate; Sucrose; Correctivess such as stevioside; Pectin; Gelatin; Polyoxyethylene; Thickening agents such as polyvinyl alcohol; Micropowder silica gel; Fluidizer such as Pulvis Talci etc.
Preferably, said medical dosage form is oral liquid, powder, granule, micropill, capsule and tablet.Above-mentioned dosage form is the peroral dosage form any commonly used that the method for Chinese medicinal with routine is prepared into, like tablet, capsule, dispersible tablet, effervescent tablet, buccal tablet, chewable tablet, soft capsule, microcapsule, granule, pill, powder, drop pill, slow releasing preparation, controlled release preparation or oral liquid etc.
Two of goal of the invention of the present invention is to provide the application in the medicine of aforementioned pharmaceutical compositions in preparation treatment type ii diabetes.
Three of goal of the invention of the present invention is to provide the application of aforementioned pharmaceutical compositions in the medicine of preparation treatment high fat of blood.
Four of goal of the invention of the present invention is to provide aforementioned pharmaceutical compositions preparing treatment with the application in the medicine of the diabetes of hyperlipidemia.
Preparation of drug combination method of the present invention comprises the steps:
(1) carry with alcohol extraction or water according to conventional method and extract guava extract respectively, subsequent use;
(2) according to above-mentioned prescription mixing guava extract, Radix Oenotherae erythrosepalae oil with contain chromium compound, add pharmaceutically acceptable pharmaceutic adjuvant, be prepared into medical dosage form or functional health product.
The extract of the Chinese medicinal components that adopts of the present invention can be carried or dipping, the reflux, extract, of alcohol extraction (comprising aqueous methanol, ethanol, propanol, ethylene glycol etc.) for water; Merge extractive liquid; Concentrating under reduced pressure, drying, pulverizing; Obtain the extract of each natural drug, can also can provide for oneself from direct purchase.
Radix Puerariae is the tuber of pulse family Herba Gelsemii Elegantis; Through extraction, separation and evaluation to the Radix Puerariae main component; Find that puerarin has blood sugar lowering, expansion peripheral blood vessel, particularly effects such as coronary artery dilator blood vessel, anticoagulant; Thereby had the treatment diabetes, and improved peripheral nerve injury and the effect of retinopathy and renal function pathological changes due to its microangiopathies.Radix Puerariae extract has been broken through the single theory of treatment diabetes blood sugar lowering, in blood sugar lowering, is intended to repair patient's pancreas self-healing system.The pancreas self-healing system is a self regulation and the endocrine system of balance, and when blood glucose was too high in the body, the pancreas self-healing system increased the secretion of insulin amount automatically, promotes the utilization synthetic and glucose of glycogen that blood glucose is reduced.In the time will hypoglycemia occurring, the pancreas self-healing system reduces the secretion of insulin amount again automatically, to keep the stable of blood glucose.But when pancreas is impaired when obstacle occurring, this steady statue will be broken, and it is unusual islet function to occur.Like the islet function hyposecretion, insulin resistant, its result causes sugar, lipometabolic disorder---the ultimate principle of Here it is onset diabetes.The treatment diabetes restart the self-healing system of islets of langerhans as long as repair good impaired islet cells, let patient's pancreas self-healing system running recover normal, the balance secretion of insulin, and diabetes could thoroughly rehabilitation.Radix Puerariae extract can be answered pancreas and reformed; Recover islet function exactly, promote the regeneration of B cell, make its excreting insulin normally; Improve the state of hypoinsulinism; And swash the Insulin receptor INSR that in vivo is in resting state, and improve the sensitivity and the affinity of Insulin receptor INSR, improve the state of its " insulin resistant ".
In addition, the Radix Puerariae effective extract toxin expelling of invigorating blood circulation, so-called toxin expelling is removed the poison of intravital blood glucose exactly, the poison of MDA under the poison of blood fat and the free radical effect.These toxicants are intravital rubbish, are the bases that produces complication.MDA in the blood plasma is that satisfied fatty acid receives the free radical effect and forms in the body.The activity of the intravital superoxide dismutase of middle and elderly diabetic patient (we are accustomed to claiming SOD) reduces.Therefore it removes the ability drop of free radical, and lipid metabolic disorder causes microcirculation disturbance to cause blood flow to slow down simultaneously, and forms blood stasis.So-called prolonged illness in the traditional Chinese medical science that Here it is and the stasis of blood.Radix Puerariae extract can improve circulatory disturbance, makes blood stasis obstacle in the body, and blood stasis being improved invigorate blood circulation thus toxin expelling is the basis of complication prevention.
The Radix Astragali is the dry root of leguminous plant Radix Astagali or Radix Astragali.Its main component is astragalus polysaccharides class material, astragaloside, flavonoid and contains total amount and be about multiple compositions such as 1.23% 25 seed amino acids, 23 kinds of trace element (wherein ferrum, manganese, zinc, Se content are higher), folic acid, choline, linolenic acid.Astragalus polysaccharides because of its in enhancing human body immunity power. blood sugar lowering, there is stronger activity the defying age aspect and receives much concern.Research shows that astragalus polysaccharides has dual regulation.It can make the mouse blood sugar of glucose load obviously reduce, and the mouse blood sugar that also can obviously cause antiadrenergic drug raises and reacts, and it can also obviously resist the mouse experiment property hypoglycemia that phenformin causes.But it does not have obvious influence to islets of langerhans disposition hypoglycemia.Astragalus polysaccharides is from regulating the metabolism aspect performance antidiabetic effect of liver.Liver is digestive organs important in the body, and it participates in keeping the stable of blood glucose through synthetic and decomposition glycogen.Abundant endoplasmic reticulum is participated in proteic synthetic, secretion and steric configuration formation in the liver.If endoplasmic reticulum generation stress, cell will make some protein synthesis reduce, make some protein structures unusual, comprise that therefore the proteic quality and quantity of insulin and those assistance insulin actions all can be undesired, cause diabetes to take place.Astragalus polysaccharides alleviates the endoplasmic reticulum damage through improving the er stress of liver, and it is active to increase glycogen synthetase, increases insulin signaling albumen synthetic quantity and activity, thus the performance antidiabetic effect.
Fructus Momordicae charantiae contains steroid saponin such as Charantin, para-insulin peptide class and alkaloid, and these materials are given the balsam pear hypoglycemic activity.Charantin stimulates the release of insulin and hinders the formation of glucose in the blood flow, and this function possibly particularly play enormous function in the non-insulin-dependent diabetes mellitus treatment in diabetes.Fructus Momordicae charantiae effectively extract composition from suppress small intestinal mucosa to the absorption of glucose or directly play similar insulin be used for bringing into play blood sugar reducing function; Modern medicine study is found; The composition that plays the blood sugar lowering effect in the Fructus Momordicae charantiae mainly is divided into two types by its character: one type is alkaloid, like Fructus Momordicae charantiae glucoside, Fructus Momordicae charantiae saponin etc.; Another kind of is protein and peptide, is maximum, the most significant part of blood sugar decreasing effect of content in the Fructus Momordicae charantiae.The exploitation of current bitter gourd sugar-reducing medicine mainly concentrates on separate preparation, character and the pharmacologically active of polypeptide and saponin and protects the research aspect.Having separated the Momordi glucose-reducing polypeptide that obtains has a variety of.Discover that Momordi glucose-reducing polypeptide can suppress the absorption of small intestinal mucosa to glucose; Through the activity of enhance muscle endoenzyme, glucose metabolism of acceleration bodies meat and utilization make the glucose metabolism balance, promote or improve insulin secretion, or directly play the effect of similar insulin, influence intravital carbohydrate metabolism process.
Radix Oenotherae erythrosepalae oil is the most important nutrient drug of finding this century.Seed oil-containing 20～30%, 70% is linoleic acid in the oil, 8～9% are the gamma-Linolenic acid of needed by human (can reduce the cholesterol of " bad " in the body, the prevention cardiovascular and cerebrovascular disease).Radix Oenotherae erythrosepalae oil can be treated multiple disease; Regulate lipid material in the blood; Diseases such as the coronary artery infraction that hypercholesterolemia, hyperlipidemia are caused, atherosis and cerebral thrombosis have significant curative effect, also can treat multiple sclerosis, diabetes, obesity, rheumatic arthritis and schizophrenia etc.Radix Oenotherae erythrosepalae oil contains abundant gamma-Linolenic acid (GLA), can be converted into PEG2, PGI2, PGF2a, has tangible blood fat reducing and antiplatelet aggregative activity.Gamma-Linolenic acid has tangible cholesterol reducing effect, and it is renderd a service to linoleic 163 times.Radix Oenotherae erythrosepalae oil can make high fat rat blood serum T-CHOL low-density lipoprotein cholesterol, C-VLDL reduce, and the high density cholesterol levels is significantly raise.The variation of HDL-C is because the high density lipoprotein subclasses cholesterol levels raises, and the outer cholesterol levels of high density lipoprotein subclasses does not have significant change.Cause hyperlipidemia pathology model for Wistar rats gavaged hyperlipidemia modeling agent or etherosulfuric acid, the result shows that Radix Oenotherae erythrosepalae oil and sodium salt thereof have stronger blood fat reducing and study of anti-atherogenic effect.These article can be participated in the synthetic and balance of prostaglandin.Still the obviously effect of the synthetic thromboxane A2 (TXA2) of anticoagulant and platelet, thereby the ratio of change TXA2/PGI2, the effect with control thrombosis property cardiovascular disease.Gamma-Linolenic acid has stimulation to BAT, promotes the mitochondrial activity of brown fat acid, consumes too much heat and reaches certain fat-reducing effect.
Ecdysterone contained in the Folium Mori extract all has blood sugar reducing function to the inductive blood sugar increasing of several different methods, can promote that conversion of glucose is a glycogen, but not change intact animal's blood glucose.Discover that contained some aminoacid can stimulate secretion of insulin with blood sugar lowering in the Folium Mori.
Radix Ophiopogonis sweet Han Zhirun, the property that tool is cloudy gentle, the merit of YIN nourishing; Be good at clearly supporting the wet weather of lung stomach and moisturize, can clear away heart-fire again through heat and relieving restlessness is to grow the tonification good medicine that has both clearly simply; Be accessory drugs in this prescription, intravital surrounding tissue is reduced the opposing of insulin, impel islet cells to recover normal.
Pharmaceutical composition of the present invention is quality controllable, the trend that to have the fixing compound preparation of forming be the treatment diabetes, and chemicals often has the different side effect of weight, and drug combination can increase the incidence rate of side effect, brings hidden danger for the drug safety of extensive patients.For a change this situation all the time, attempts treating with botanical herbs clinically always.But when Chinese medicine uses separately,, exist onset slow, need the shortcoming of dialectical use under the experienced traditional Chinese medical science instructs though have certain hypoglycemic effect.Therefore, the present invention attempts Chinese medicine and Western medicine are combined, and avoids shortcoming separately, produces synergism simultaneously.The present invention attempts adding the chemicals that contains chromium first; When necessary elemental chromium lacks in additional diabetes human body; Be surprised to find that it and can produce synergism between the effective ingredient of Chinese medicine extract such as Fructus psidii guajavae immaturus; Glycometabolic each approach is started with in the body, played comprehensively, significantly, the effects of radical cure diabetes.
It is in the compositions of main pharmacodynamics composition that the medicinal compound that pharmaceutical composition of the present invention will contain chromium ion joins with the guava extract; The two has produced synergism efficiently surprised discovery; The adding of trace chromium ionic compound; To the main sugar-lowering components flavonoid in the guava extract and polysaccharide played purpose less than sensitization; Greatly reduce the consumption of effective ingredient guava extract when obtaining identical drug effect, improved curative effect of medication, practiced thrift production cost, improved the patient compliance, reduced the untoward reaction of medicine and the generation of side effect, particularly alleviated the generation of gastrointestinal upset significantly.Simultaneously; Usually with hyperlipidemia etc., the pathomechanism that hyperglycemia, hyperlipidemia etc. communicates creatively adds a certain proportion of Radix Oenotherae erythrosepalae oil to present diabetics; Pharmacological evaluation shows that blood sugar reducing component and component for reducing blood fat also have synergism each other; Blood glucose and blood fat can be reduced simultaneously, and have no adverse reaction, still do not have research report in this respect at present.
Pharmaceutical composition of the present invention is with having the Chinese herbal medicine extract of different pharmacological actions to combine according to a certain percentage with chemical classes medicine chromium picolinate, making compound preparation; Each composition through to influence in the body glycometabolic each approach exert an influence play collaborative from effect; Start with from producing hyperglycemia, each organ of hyperlipidemia, mechanism, repair one by one and perfect, for example replenish the trace chromium element that lacks in the diabetes human body, glycometabolic influence in the liver; Reparation influence to pancreas; Mucous membrane of small intestine is heavily absorbed the influence of glucose, replenish many-sides such as necessary aminoacid, linolenic acid and play a role, produced beyond thought blood sugar lowering, consolidated, repair three bonded effects; Fundamentally play the effect of blood sugar lowering, blood fat reducing, and combine pharmacological evaluation that the present invention has been carried out further checking.Chinese medicine ingredients and western medicine composition are brought into play synergism; The determined curative effect of existing Western medicine, onset be advantage rapidly; Can bring into play in the Chinese medicine composition all medicines again assists with, the monarch and his subjects mutually mutually; The effect of the abnormal metabolism in the balance human body is to diabetes, hyperlipidemia, especially play the effect of treating both the principal and secondary aspects of a disease with the type ii diabetes of hyperlipidemia.With natural drug effective site is primary raw material, has the characteristic of hypotoxicity and low untoward reaction.Through the righttest combination in the Chinese medicine compound, find the compositions ratio of optimum medicine efficacy, save cost, be convenient to clinical practice.Preparation technology is simple, and the composition of effective site is confirmed, is convenient to quantitatively help industrialized great production.
The specific embodiment
To combine embodiment and Test Example to introduce pharmaceutical composition of the present invention in detail below.
Embodiment 1
In Fructus psidii guajavae immaturus, add 10 times of amount 50% alcoholic solution, dipping, reflux, extract, under 50 ℃, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain extract.
With the 50g guava extract, add 0.3g Radix Oenotherae erythrosepalae oil, 0.02g chromium picolinate (weight that is scaled chromium is calculated), add an amount of excipient microcrystalline Cellulose, disintegrating agent carboxymethyl base Starch Sodium and hypromellose, magnesium stearate lubricant etc. again; Cross 100 mesh sieves, mixing is with 75% ethanol system soft material; 12 mesh sieves are granulated, 55 ℃ of dryings 3 hours, 14 mesh sieve granulate; Add micropowder silica gel, mixing, tabletting, both pharmaceutical composition tablet of the present invention (1000 preparations).
Embodiment 2
Add 10 times of amount 50% alcoholic solution Fructus psidii guajavae immaturus, dipping, reflux, extract, under 50 ℃, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain extract.
With the 100g guava extract, add 1g Radix Oenotherae erythrosepalae oil, 0.08g nicotinic acid chromium (weight that is scaled chromium is calculated), add an amount of excipient microcrystalline Cellulose, disintegrating agent carboxymethyl base Starch Sodium and hypromellose, magnesium stearate lubricant etc. again; Cross 100 mesh sieves, mixing is with 75% ethanol system soft material; 12 mesh sieves are granulated, 55 ℃ of dryings 3 hours, 14 mesh sieve granulate; Add micropowder silica gel, mixing, tabletting, both pharmaceutical composition tablet of the present invention (1000 preparations).
Embodiment 3
Prepare Powdered guava extract (can buy) 200g, adding 0.15g Radix Oenotherae erythrosepalae oil, 0.2g Chlorizate chromium (weight that is scaled chromium is calculated), mix homogeneously adds suitable amount of sucrose, starch and dextrin again; Cross 100 mesh sieves, mixing, an amount of with starch slurry; Process soft material, 12 orders are granulated, 55 ℃ of dryings; 16 order granulate, pack makes granule.
Embodiment 4
Prepare Powdered guava extract (can buy) 180g, adding 1.8g Radix Oenotherae erythrosepalae oil, 0.15g chromic oxide (weight that is scaled chromium is calculated), 0.03g nicotinic acid chromium (weight that is scaled chromium is calculated), mix homogeneously adds suitable amount of sucrose, starch and dextrin again; Cross 100 mesh sieves, mixing, an amount of with starch slurry; Process soft material, 12 orders are granulated, 55 ℃ of dryings; 16 order granulate, pack makes granule.
Embodiment 5
In Fructus psidii guajavae immaturus, add 10 times of amount 50% alcoholic solution, dipping, reflux, extract, under 50 ℃, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain extract.
With the 80g guava extract, add 2g Radix Oenotherae erythrosepalae oil, 0.05g nicotinic acid chromium (weight that is scaled chromium is calculated), 0.05 chromium carbonate (weight that is scaled chromium is calculated), add an amount of excipient microcrystalline Cellulose, disintegrating agent carboxymethyl base Starch Sodium and hypromellose, magnesium stearate lubricant etc. again; Cross 100 mesh sieves; Mixing, with 75% ethanol system soft material, 12 mesh sieves are granulated; 55 ℃ of dryings 3 hours; 14 mesh sieve granulate add micropowder silica gel, mixing, tabletting, both pharmaceutical composition tablet of the present invention (1000 preparations).
Embodiment 6
In Fructus psidii guajavae immaturus, add 10 times of amount 50% alcoholic solution, dipping, reflux, extract, under 50 ℃, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain extract.
With the 130g guava extract, add 0.11g Radix Oenotherae erythrosepalae oil, 0.15g chromium carbonate (weight that is scaled chromium is calculated), add an amount of excipient microcrystalline Cellulose, disintegrating agent carboxymethyl base Starch Sodium and hypromellose, magnesium stearate lubricant etc. again; Cross 100 mesh sieves, mixing is with 75% ethanol system soft material; 12 mesh sieves are granulated, 55 ℃ of dryings 3 hours, 14 mesh sieve granulate; Add micropowder silica gel, mixing, tabletting, both pharmaceutical composition tablet of the present invention (1000 preparations).
Embodiment 7
Respectively with the methanol and 50% alcoholic solution that add 10 times of amounts 50% in Fructus psidii guajavae immaturus, the Radix Puerariae, 50 ℃ of dipping, reflux, extract, down, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain the extract of each natural drug
In 160g guava extract, 70g Radix Puerariae extract, add 1.5g Radix Oenotherae erythrosepalae oil, 0.15g chromium carbonate (weight that is scaled chromium is calculated), add an amount of excipient microcrystalline Cellulose, disintegrating agent carboxymethyl base Starch Sodium and hypromellose, magnesium stearate lubricant etc. again; Cross 100 mesh sieves, mixing is with 75% ethanol system soft material; 12 mesh sieves are granulated, 55 ℃ of dryings 3 hours, 14 mesh sieve granulate; Add micropowder silica gel, mixing, tabletting, both pharmaceutical composition tablet of the present invention (1000 preparations).
Embodiment 8
The methanol and 50% alcoholic solution that respectively Fructus psidii guajavae immaturus, Radix Puerariae, the Radix Astragali are added 10 times of amounts 50%, 60 ℃ of dipping, reflux, extract, down, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain the extract of each natural drug.
In 70g guava extract, 50g Radix Puerariae extract, 30g Radix Astragali extract, add 1.5g Radix Oenotherae erythrosepalae oil, 0.15g chromium carbonate (weight that is scaled chromium is calculated), mix homogeneously; Add suitable amount of sucrose, starch and dextrin again, cross 100 mesh sieves, mixing; An amount of with starch slurry, process soft material, 12 orders are granulated; 55 ℃ of dryings, 16 order granulate, pack makes granule.
Embodiment 9,
Respectively with Fructus psidii guajavae immaturus, the Radix Astragali, Fructus Momordicae charantiae, add the methanol and 50% alcoholic solution of 10 times of amounts 50% in Radix Ophiopogonis, 50 ℃ of dipping, reflux, extract, down, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain the extract of each natural drug.
Preparation process: take by weighing each extract according to said ratio, add 0.3g Radix Oenotherae erythrosepalae oil, 0.05g chromium picolinate (weight that is scaled chromium is calculated), add an amount of excipient microcrystalline Cellulose, disintegrating agent carboxymethyl base Starch Sodium and hypromellose, magnesium stearate lubricant etc. again; Cross 100 mesh sieves, mixing is with 75% ethanol system soft material; 12 mesh sieves are granulated, 55 ℃ of dryings 3 hours, 14 mesh sieve granulate; Add micropowder silica gel, mixing, tabletting, both pharmaceutical composition tablet of the present invention (1000).
Embodiment 10,
Respectively with the methanol and 50% alcoholic solution that add 10 times of amounts 50% in Fructus psidii guajavae immaturus, the Radix Astragali, Fructus Momordicae charantiae, the Folium Mori, 50 ℃ of dipping, reflux, extract, down, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain the extract of each natural drug.
Preparation process: take by weighing the extract of each component according to said ratio, add 0.5g Radix Oenotherae erythrosepalae oil, 0.09g chromium picolinate (weight that is scaled chromium is calculated), mix homogeneously; Add suitable amount of sucrose, starch and dextrin again, cross 100 mesh sieves, mixing; An amount of with starch slurry, process soft material, 12 orders are granulated; 55 ℃ of dryings, 16 order granulate, pack makes granule.
Embodiment 11
Utilize the method for embodiment 5 to prepare pharmaceutical composition of the present invention.Difference is, is prescription according to following listed component:
Embodiment 12
Utilize the method for embodiment 6 to prepare pharmaceutical composition of the present invention.Difference is, is prescription according to following listed component:
Embodiment 13
Utilize the method for embodiment 6 to prepare pharmaceutical composition of the present invention.Difference is, is prescription according to following listed component:
Embodiment 14,
Respectively with 50% methanol and 20% propanol solution that add 10 times of amounts in Fructus psidii guajavae immaturus, Radix Puerariae, the Radix Astragali, the Fructus Momordicae charantiae, 50 ℃ of dipping, reflux, extract, down, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain the extract of each natural drug.
Dried powder according to each natural drug extract of above-mentioned recipe quantity is a raw material, adds 1g Radix Oenotherae erythrosepalae oil, 0.25g chromium picolinate (weight that is scaled chromium is calculated), as principal agent; With the water-soluble adding glycerol of gelatin, transfer to suitable color, be incubated set aside for use (diluent) after the vacuumize degassing; Solubilizing agent PEG-400 (Polyethylene Glycol), antioxidant vitamin E, pH regulator agent phosphate buffer, dehydrated alcohol are added in the diluent, and principal agent is dissolved in wherein, both mix homogeneously; 50-60 ℃ of reduction vaporization removed ethanol, gets settled solution; The medicinal liquid for preparing is poured in the pellet processing machine, finalized the design, put drying, scrape and promptly get soft capsule prepn (1000 preparations).
Embodiment 15,
Preparation technology: add 60% alcoholic solution of 10 times of amounts with Fructus psidii guajavae immaturus, the Radix Astragali, Fructus Momordicae charantiae, in Radix Ophiopogonis, 50 ℃ of dipping, reflux, extract, down, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain the extract of each natural drug;
Dried powder with each natural drug extract of above-mentioned recipe quantity is a raw material; Add 0.5g Radix Oenotherae erythrosepalae oil, 0.05g chromium picolinate (weight that is scaled chromium is calculated); Add tartaric acid, sodium bicarbonate, sweeting agent, filler mixing, granulate drying with dehydrated alcohol; Add the lubricant mixing, tabletting prepares effervescent tablet (1000 preparations).
Embodiment 16,
Preparation technology: with 60% alcoholic solution that adds 10 times of amounts in Folium Psidii Guajavae, Fructus psidii guajavae immaturus sarcocarp, the Radix Astragali, 50 ℃ of dipping, reflux, extract, down, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing obtain the extract of each natural drug;
Dried powder with each natural drug extract of above-mentioned recipe quantity is a raw material; Add 0.9g Radix Oenotherae erythrosepalae oil, 0.07g chromium picolinate (weight that is scaled chromium is calculated); Add adjuvant, filler commonly used in the food, sieve, tabletting behind the mixing, make functional health product (1000 preparations).
Embodiment 17,
Add the water of 10 times of amounts and the mixed solution of 50% methanol solution (1: 1) with Folium Psidii Guajavae, Fructus psidii guajavae immaturus sarcocarp, Fructus Momordicae charantiae, Folium Mori, in Radix Ophiopogonis; Dipping, reflux, extract, under 50 ℃, merge extractive liquid,, concentrating under reduced pressure, drying, pulverizing; Obtain the extract of each natural drug, subsequent use.
Dried powder with each natural drug extract of above-mentioned recipe quantity is a raw material; Add Radix Oenotherae erythrosepalae oil 0.8g, 0.1g chromium picolinate (weight that is scaled chromium is calculated); Mix the back with ethyl cellulose, hydroxypropyl methylcellulose, magnesium stearate and granulate, tabletting makes slow releasing tablet (1000 preparations).
The pharmaceutic adjuvant that uses among above-mentioned each embodiment of the present invention all is a pharmaceutic adjuvant acceptable in the commonly used or medication preparation in the medication preparation like diluent, disintegrating agent, excipient, binding agent, lubricant, surfactant, filler, antiseptic, stabilizing agent, correctives, thickening agent, fluidizer etc.The dosage form that the dosage form of pharmaceutical composition of the present invention is not limited to enumerate out in the foregoing description; Also available conventional method is prepared into other common dosage forms, like tablet, capsule, dispersible tablet, buccal tablet, chewable tablet, microcapsule, granule, pill, powder, drop pill, slow releasing preparation, controlled release preparation, oral liquid etc.The extract of each Chinese medicinal components of the present invention can directly be bought from market, and its preparation method is also for pharmaceutical field water or pure extracting method commonly used, so do not make more detailed description here.
One, experimental example
The present invention verifies further that through pharmacology, the test of pesticide effectiveness Chinese medicine compound compositions that adopts the present invention to make has hypoglycemic effect significantly, and the adding of chromium ion has reduced the consumption of effective medicinal ingredient significantly.
One, to Pharmacological action study
1, to the influence of normal mouse blood sugar (table 1), body weight and food ration (2):
Get 60 of normal mouses (23 ± 2g), be divided into 3 groups at random, 20 every group;
(1) pharmaceutical composition of the present invention (80mg guava extract+0.02mg chromium picolinate): give and 80mg/kg;
(2) guava extract: give and guava extract 300mg/kg;
(3) normal control group: give and normal saline;
Gastric infusion, continuous 10 days, 5h and 12h surveyed blood glucose after the last administration, and the result is following:
The influence of table 1 pair normal mouse blood sugar
The result shows that behind pharmaceutical composition group of the present invention and guava extract group mice fasting 5h and the 12h, blood sugar level is a little less than the normal control group, but no significant difference.
The influence of table 2 pair normal mouse body weight and food ration
| Group | Body weight average (g) | Food ration average (g/ day) |
| Pharmaceutical composition group of the present invention | 22±2g | 10±2g |
| The guava extract group | 16±2g | 4±2g |
| The normal control group | 24±2g | 12±3g |
The result shows; Present composition group is approaching to the zest and the normal group of mouse GI tract, mice appetite no change, the body weight average and every day food ration average zero difference; But heavy dose of guava extract is big to the mouse GI tract stimulus effects; Can be observed the mice inappetence, be a cup too low, the body weight average and every day the food ration average have significant difference.
2, to the influence of glucose sugar property hyperglycemia mouse blood sugar
Test method: get normal mouse, be divided into 11 groups at random, 15 every group.Guava extract group administration 300mg/kg, pharmaceutical composition of the present invention (with Test Example 1) administration 80mg/kg, normal control group, model control group are given with distilled water, positive controls and are given and glipizide 5mg/kg; Equal gastric infusion, continuous 10 days, last was irritated the preceding fasting 10h of stomach; After irritating stomach 1h, normal control group intraperitoneal injection of saline, all the other respectively organize lumbar injection glucose sugar 3g/kg; Behind the 1h, the tail vein is surveyed blood glucose.
The result is following:
The influence of table 3 pair glucose property hyperglycemia mouse blood sugar
| Group | Blood glucose value (mmol/L) |
| The normal control group | 5.13±0.73 |
| Model control group | 25.12±1.97 △△ |
| The glipizide group | 12.21±2.32 **△△ |
| Present composition group | 9.75±1.47 **△△ |
| The guava extract group | 15.69±2.47 **△△ |
Annotate:
*P＜0.05,
*Compare with the normal control group in P＜0.01, △ P＜0.05, △ △ P＜0.01.
The result shows: lumbar injection glucose induction mouse blood sugar significantly raises (P＜0.01), and glipizide, the present composition, guava extract be the significantly rising of antagonism mouse blood sugar level all, and the blood sugar lowering rate of compositions of the present invention is superior to other groups.
The influence of table 4 pair glucose property hyperglycemia mice body weight and food ration
| Group | Body weight average (g) | Food ration average (g/ day) |
| The normal control group | 24±2g | 12±2g |
| Model control group | 25±2g | 15±2g |
| The glipizide group | 20±2g | 12±3g |
| Present composition group | 22±2g | 10±2g |
| The guava extract group | 16±2g | 4±2g |
The result shows; The present composition, glipizide are approaching to the zest and the normal group of mouse GI tract, mice appetite no change, the body weight average and every day food ration average zero difference; But heavy dose of guava extract is big to the mouse GI tract stimulus effects; Can be observed the mice inappetence, be a cup too low, the body weight average and every day the food ration average have significant difference.
3, to the influence of adrenal gland's disposition hyperglycemia mouse blood sugar
Get 165 of normal mouses, grouping and administration are with above-mentioned glucose sugar property hyperglycemia mouse blood sugar influence test item down.Fasting 10.5h before the last administration, behind the gastric infusion 0.5h, normal control group subcutaneous injection normal saline, other group subcutaneous injection epinephrines 1mg/kg, behind the 1h, the tail vein is surveyed blood glucose, and the result is following:
Table 5 compound is to the influence of adrenal gland's disposition hyperglycemia mouse blood sugar
Annotate:
*P＜0.05,
*Compare with the normal control group in P＜0.01, △ P＜0.05, △ △ P＜0.01.
The result shows that subcutaneous injection epinephrine inducing mouse blood glucose significantly raises (P＜0.01), and glipizide, the present composition, guava extract be the significantly rising of antagonism mouse blood sugar level all, and the blood sugar lowering rate of compound is superior to other groups.
4, chain is urinated blood sugar lowering, the effect for reducing blood fat of rhzomorph-diabetes rat
Test method: get the normal male rat, lumbar injection chain urine rhzomorph 180mg/kg causes diabetes model.Be divided into 9 groups at random, 13 every group.Present composition group administration 85.2mg/kg (80mg guava extract+0.2mg chromium picolinate+5mg Radix Oenotherae erythrosepalae oil); Guava extract group administration 300mg/kg normal control group, model control group are given and distilled water, and positive controls gives glipizide 5mg/kg, all gastric infusion; After 3 weeks of administration; Last is irritated the preceding fasting 2h of stomach, and 1h tail vein was surveyed blood glucose after last was irritated stomach, and the result is following:
Table 6 compound is urinated the influence of rhzomorph-rat diabetes, blood fat to chain
| Group | Blood glucose (mmol/L) | Triglyceride (mmol/L) |
| The normal control group | 5.19±0.53 | 0.89±0.12 |
| Model control group | 27.47±4.55 △△ | 4.21±1.16 △△ |
| The glipizide group | 19.35±1.76 **△△ | 3.92±0.96 **△△ |
| Present composition group | 17.75±2.92 **△△ | 1.32±1.17 **△△ |
| The guava extract group | 20.15±2.96 **△△ | 4.15±1.69 **△△ |
Annotate:
*P＜0.05,
*P＜0.01. compares with the normal control group, △ P＜0.05, △ △ P＜0.01.
The result shows: glipizide, the present composition, guava extract all can reduce the mouse blood sugar level, and the blood sugar lowering rate of the present composition is superior to other groups; The present composition can significantly reduce the mice blood lipid level, and guava extract, glipizide can reduce the mice blood lipid level slightly.
5, synergistic action effect experiment between each component in the pharmaceutical composition of the present invention:
Having set up high sugar induces rat insulin opposing model-SD rat to give normal diet (carbohydrate 60%, fat 11%, protein 29%) 4 weeks of nursing; Rat is fed with high fructose feedstuff (fructose 66%, fat 12%, protein 22%), after spending for 4 weeks, can become mould.
Be reference substance with commercially available rosiglitazone maleate sheet, XIAOKE JIANGTANG JIAONANG (guava extract capsule) then; With FPG (blood glucose), HbAlc (glycolated hemoglobin) is index, investigates the blood sugar reducing function of these article (pharmaceutical composition that adopts embodiment 1,2,7,8,9,10,14,15,16,17 is as test specimen).Its result sees table 5.
The variation of the forward and backward blood glucose of table 7 treatment, glycolated hemoglobin
Can know by table, have significant difference, pharmaceutical composition of the present invention between each treatment group (experimental group); Because the drug combination of pharmaceutically active ingredient in each; Reach the synergism that produces with the chemicals chromium picolinate that adds first, have significant hypoglycemic effect, compare with other Chinese medicine preparation that produce same effect; Reduce the consumption of each component, reduced toxic and side effects.And the proportioning effect that can be known each component in the pharmaceutical composition that embodiment 9 makes by table 7 more is superior to other prescriptions.
Two, acute toxicity test
Test method: get 60 of mices, fasting is divided into 3 groups after 16 hours at random; Each 10 of every group of male and female; By adult (body weight 65kg) 2.7g compound consumption calculating for each person every day, be converted into per kilogram of body weight 41.5mg every day, enlarge the administration of 100 times of disposable per os mouse stomaches with this dosage; In two weeks, observe and record poisoning symptom and death condition, calculate LD50 with the Bliss method.The result shows: 1. do not find poisoning symptom and death condition; 2. female, male its mouse oral LD50 is all greater than 4.15g/KGBW.Judge that according to acute toxicity grading criteria in " toxicological evaluation of food safety procedure and method " this compound belongs to the non-toxic type material.
The above is merely preferred embodiment of the present invention, and is in order to restriction the present invention, not all within spirit of the present invention and principle, any modification of being done, is equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (8)
1. pharmaceutical composition is characterized in that it contains the component of following parts by weight:
Extract 20-200 part of Fructus psidii guajavae immaturus is contained medicinal compound 0.01-0.2 part of chromium ion, Radix Oenotherae erythrosepalae oil 0.1-2 part;
Said guava extract is obtained after through alcohol extraction or water extraction, drying and crushing by Fructus psidii guajavae immaturus, and its active ingredient is Fructus psidii guajavae immaturus total flavonoid, Fructus psidii guajavae immaturus polysaccharide and Fructus psidii guajavae immaturus polyphenol;
The medicinal compound that contains chromium ion is one or more in chromium picolinate, nicotinic acid chromium, chromic oxide gel, chromium carbonate, chromic oxide and the Chlorizate chromium, and its content is the weight in chromium.
2. pharmaceutical composition according to claim 1; It is characterized in that also containing in the said composition in Radix Puerariae extract, Radix Astragali extract, Fructus Momordicae charantiae extract, Radix Ophiopogonis, the Folium Mori extract one or more, wherein the weight portion of Radix Puerariae extract is that the weight portion of 40-200, Radix Astragali extract is that the weight portion of 20-170, Fructus Momordicae charantiae extract is that the weight portion of 10-100, Radix Ophiopogonis is that the weight portion of 20-170, Folium Mori extract is 20-170;
Said Radix Puerariae extract, Radix Astragali extract, Fructus Momordicae charantiae extract and Folium Mori extract are obtained after through alcohol extraction or water extraction, drying and crushing by Radix Puerariae, the Radix Astragali, Fructus Momordicae charantiae and Folium Mori respectively, and its effective ingredient is respectively puerarin and Radix Puerariae flavone, astragalus polysaccharides, Charantin and Fructus Momordicae charantiae para-insulin, Folium Mori alkaloid compounds.
3. pharmaceutical composition according to claim 2 is characterized in that said composition contains the component of following parts by weight:
Guava extract 50-100 part, chromium picolinate 0.025-0.1 part,
Radix Astragali extract 30-160 part, Fructus Momordicae charantiae extract 10-100 part,
Radix Ophiopogonis 30-160 part, Radix Oenotherae erythrosepalae oil 0.15-1 part,
The parts by weight of wherein said chromium picolinate are with the cubage of chromium.
4. pharmaceutical composition as claimed in claim 1 is characterized in that also comprising pharmaceutically acceptable carrier auxiliary material, is prepared into medical dosage form or functional health product.
5. pharmaceutical composition as claimed in claim 4 is characterized in that said medical dosage form is tablet, capsule, granule, powder, drop pill or oral liquid.
6. pharmaceutical composition as claimed in claim 1, the application in the medicine of preparation treatment type ii diabetes.
7. pharmaceutical composition as claimed in claim 1, the application in the medicine of preparation treatment high fat of blood.
8. pharmaceutical composition as claimed in claim 1 is preparing treatment with the application in the medicine of the diabetes of hyperlipidemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102825443A CN101940620B (en) | 2010-09-14 | 2010-09-14 | Medicinal composition for treating diabetes mellitus and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102825443A CN101940620B (en) | 2010-09-14 | 2010-09-14 | Medicinal composition for treating diabetes mellitus and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101940620A CN101940620A (en) | 2011-01-12 |
| CN101940620B true CN101940620B (en) | 2012-07-04 |
Family
ID=43432951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102825443A Expired - Fee Related CN101940620B (en) | 2010-09-14 | 2010-09-14 | Medicinal composition for treating diabetes mellitus and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101940620B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375914A (en) * | 2017-09-18 | 2017-11-24 | 郭恒立 | A kind of Chinese medicinal plaster preparation and application for treating type II diabetes and complication |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102885300A (en) * | 2012-09-19 | 2013-01-23 | 无锡市天赐康生物科技有限公司 | Health-care food with blood sugar reducing effect and preparation method thereof |
| CN103083470B (en) * | 2013-01-28 | 2014-10-22 | 汤臣倍健股份有限公司 | Balsam pear and kudzu root slice with functions of decreasing blood sugar |
| CN103610752A (en) * | 2013-11-21 | 2014-03-05 | 华侨大学 | Functional food with hypoglycemic effect and preparation method thereof |
| CN103784727B (en) * | 2014-02-25 | 2017-03-22 | 湖南希尔天然药业有限公司 | Folium mori compound preparation and application thereof |
| CN104757424A (en) * | 2015-03-18 | 2015-07-08 | 毛清奎 | Eurycoma longifolia compound granule and preparation method thereof |
| CN105166926A (en) * | 2015-08-10 | 2015-12-23 | 云南师范大学 | Wild guava oral administration tablets capable of reducing blood sugar and resisting oxidation and preparation method of wild guava oral administration tablets |
| CN105412604A (en) * | 2015-12-16 | 2016-03-23 | 李传艳 | Traditional Chinese medicine composition for auxiliary treatment of diabetes and preparation method of traditional Chinese medicine composition |
| WO2017137405A1 (en) * | 2016-02-10 | 2017-08-17 | Pm-International Ag | Composition containing guaijaverin for reducing and/or suppressing an intestinal glucose resorption, nutritional supplement, use of the composition and process for producing the nutritional supplement |
| CN106943372A (en) * | 2017-03-16 | 2017-07-14 | 于桐浩 | A kind of auxiliary hyperglycemic soft capsule and its production technology |
| CN107412261A (en) * | 2017-07-26 | 2017-12-01 | 深圳安济堂医药科技有限公司 | With clear sugared oral liquid for repairing metabolic function and preparation method thereof |
| CN109123655A (en) * | 2018-08-23 | 2019-01-04 | 刘德平 | A kind of special doctor's food and preparation method with three high crowd's generation meal regulatory functions |
| CN111772074A (en) * | 2020-07-23 | 2020-10-16 | 成都通灵中药饮片精选有限公司 | Guava leaf beverage |
| CN112316013A (en) * | 2020-10-21 | 2021-02-05 | 暨南大学 | Composition containing guava and tylophora fruits and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101491582A (en) * | 2008-01-23 | 2009-07-29 | 北京因科瑞斯医药科技有限公司 | Combination with blood sugar reducing function and preparation method thereof |
-
2010
- 2010-09-14 CN CN2010102825443A patent/CN101940620B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101491582A (en) * | 2008-01-23 | 2009-07-29 | 北京因科瑞斯医药科技有限公司 | Combination with blood sugar reducing function and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 张伟敏.《苦瓜素性质及其生理功能研究概况》.《粮食与油脂》.2005,(第9期),第44-46页. * |
| 张铁军 等.第二章 延缓衰劳中药现代研究与开发.《延缓衰老和抗疲劳中药现代研究与应用》.人民卫生出版社,2007,(第1版),第16、20、26页. |
| 张铁军 等.第二章 延缓衰劳中药现代研究与开发.《延缓衰老和抗疲劳中药现代研究与应用》.人民卫生出版社,2007,(第1版),第16、20、26页. * |
| 杨雨.《桑叶不同组分降血糖作用研究》.《食品科学》.2007,第28卷(第8期),第454-456页. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375914A (en) * | 2017-09-18 | 2017-11-24 | 郭恒立 | A kind of Chinese medicinal plaster preparation and application for treating type II diabetes and complication |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101940620A (en) | 2011-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101940620B (en) | Medicinal composition for treating diabetes mellitus and application thereof | |
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN103446450B (en) | A kind of composition and method of making the same with alleviating physical fatigue function | |
| CN104740412B (en) | A kind of Medicament for Alcoholism composition and preparation method thereof | |
| WO2019056908A1 (en) | Application method of dendrobium candidum in preparing medicine for treating hypertension | |
| CN103479635A (en) | Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof | |
| CN101856405B (en) | Medicinal composition for treating type II diabetes mellitus and preparation method thereof | |
| CN101085079A (en) | Traditional Chinese medicine compound for treating diabetes and its preparation method and application | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN107569608B (en) | Pharmaceutical composition for reducing blood sugar | |
| CN107281386B (en) | Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seeds and application | |
| CN101491605A (en) | Combination with blood sugar reducing function and preparation method thereof | |
| CN103784683B (en) | A kind of Chinese medicine composition treating obesity and its preparation method and application | |
| WO2014134833A1 (en) | Edible composition, preparation method therefor, and food product comprising the composition | |
| CN115089661A (en) | Application of ginseng composition for assisting in regulating endocrine metabolism and resisting and preventing cancer | |
| CN102225082B (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| US11957726B2 (en) | Pharmaceutical composition for controlling blood sugar | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN103071010B (en) | Traditional Chinese medicine preparation for treating disorders of gastrointestinal motility | |
| CN102631487B (en) | Traditional Chinese medicine composition capable of improving immunity and resisting fatigue | |
| CN112316125B (en) | Traditional Chinese medicine composition based on hirudin and preparation method of micropills thereof | |
| CN101164595A (en) | Traditional Chinese medicine for curing anorexia | |
| CN107595866A (en) | A kind of pharmaceutical preparation for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 |